Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study

Autor:	Jia-Sin Liu, Chia Che Wu, Yen-Yang Chen, Meng-Che Hsieh, Wei-Chieh Lee, Harvey Yu-Li Su, Kun-Ming Rau
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Taiwan Pulmonary disease lcsh:Medicine survival Article 03 medical and health sciences Egfr tki 0302 clinical medicine Epidermal growth factor Internal medicine EGFR-TKI Medicine COPD Lung cancer Survival analysis business.industry lcsh:R Cancer General Medicine medicine.disease respiratory tract diseases lung cancer 030228 respiratory system 030220 oncology & carcinogenesis Propensity score matching business
Zdroj:	Journal of Clinical Medicine, Vol 8, Iss 7, p 1024 (2019) Journal of Clinical Medicine Volume 8 Issue 7
ISSN:	2077-0383
Popis:	The emergence of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) caused a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). Although several clinicopathologic factors to predict the response to and survival on EGFR-TKI were recognized, its efficacy has not been confirmed for patients with underlying pulmonary disease, such as chronic obstructive pulmonary disease (COPD). We conducted the study to evaluate the impact of COPD on survival for NSCLC patients that underwent EGFR-TKI treatment. The nationwide study obtained clinicopathologic data from the National Health Insurance Research Database in Taiwan between 1995 and 2013. Patients receiving EGRR-TKI were divided into COPD and non-COPD groups, and adjusted for age, sex, comorbidities, premium level and cancer treatments. Overall survival (OS) and progression-free survival (PFS) were calculated by Kaplan&ndash Meier analysis. In total, 21,026 NSCLC patients were enrolled, of which 47.6% had COPD. After propensity score (PS) matching, all covariates were adjusted and balanced except for age (p < 0.001). In the survival analysis, the median OS (2.04 vs. 2.28 years, p < 0.001) and PFS (0.62 vs. 0.69 years, p < 0.001) of lung cancer with COPD were significantly worse than those without COPD. Lung cancer patients on EGFR-TKI treatment had a worse survival outcome if patients had pre-existing COPD.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8fa00edbfb6144ca38ee3cfe999c78e https://www.mdpi.com/2077-0383/8/7/1024 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.